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Microbial infections are a significant threat to public health, and
resistance is on the rise, so new antibiotics with novel modes of
action are urgently needed. The extracellular zinc metallopro-
tease collagenase H (ColH) from Clostridium histolyticum is a
virulence factor that catalyses tissue damage, leading to
improved host invasion and colonisation. Besides the major role
of ColH in pathogenicity, its extracellular localisation makes it a
highly attractive target for the development of new antivir-
ulence agents. Previously, we had found that a highly selective
and potent thiol prodrug (with a hydrolytically cleavable
thiocarbamate unit) provided efficient ColH inhibition. We now
report the synthesis and biological evaluation of a range of
zinc-binding group (ZBG) variants of this thiol-derived inhibitor,
with the mercapto unit being replaced by other zinc ligands.
Among these, an analogue with a phosphonate motif as ZBG
showed promising activity against ColH, an improved selectivity
profile, and significantly higher stability than the thiol reference
compound, thus making it an attractive candidate for future
drug development.
Introduction
Due to emerging resistances against established antibacterial
agents, the treatment of bacterial infections might be thrown
back to a state similar to the pre-antibiotic era. In an estimated
worst-case scenario, it has been predicted that by 2050,
infectious diseases caused by antibiotic-resistant microbes
might lead to higher death tolls than cancer does today.[1]
Hence, there is an urgent need to develop antibiotics with
novel modes of action, high efficacy and a reduced tendency to
induce the development of resistances.[2]
A promising way of overcoming the problem of fast
resistance development is the design of so-called “pathoblock-
ers”, that is, compounds that target virulence factors rather
than vital factors of bacteria, in contrast to classical antibiotics.[3]
Bacteria that are thus “disarmed” by pathoblockers should
ideally cause either no or at least a strongly attenuated disease.
Furthermore, such pathoblocker-induced reduction of pathoge-
nicity should provide the immune system the necessary time to
develop a full humoral and cellular immune response to
eliminate the bacteria, possibly aided by a low-dose adjunctive
treatment with antibiotics.
Clostridium (including the prominent species C. difficile, C.
histolyticum (Hathewaya histolytica), C. tetani, C. botulinum, C.
septicum, and C. perfringens) is a genus of Gram-positive
anaerobic bacteria that is ubiquitous. They cause severe human
diseases such as tetanus, gas gangrene (myonecrosis), botulism,
bacterial corneal keratitis, and other dangerous infections[4] with
high mortality rates.[5] Some of these species have even been
cultivated and are bioweapons.[6]
Collagenase is a prominent virulence factor for the
progression of Clostridia-associated diseases.[7] It is a calcium-
and zinc-dependent metalloprotease that destroys the host‘s
connective tissue and uses it as a carbon source. This leads to
improved host invasion and colonisation and hence to breach-
ing of the human immune system. Also, the spread of toxins
into the damaged tissue is promoted.[5b,8] Collagens, the natural
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substrates of ColH, are the most abundant proteins of the
human extracellular matrix and can be found throughout all
organs (especially in skin, bones and joints). Their triple-helical
structure is formed by three intertwined left-handed helices
and is based on a shared repetitive Gly-Xaa-Yaa motif. In this
motif, Xaa and Yaa can be nearly any amino acid, but a proline in
the Xaa (28%) and a hydroxyproline in the Yaa (38%) position,
respectively, occur most frequently.[10]
Clostridial collagenases are multidomain proteins whose
collagenolytic core is composed of an activator domain and a
peptidase domain.[11] In the latter, the catalytic zinc ion is
coordinated by two histidines in an HEXXH motif and a
downstream glutamate.[5a,11] Mechanistically, the general acid-
base glutamate in the HEXXH motif polarises the nucleophilic
water molecule in the active site. This polarisation is further
facilitated by the zinc ion acting as a Lewis acid (promoted
water mechanism). Additionally, by polarising and stabilising
the carbonyl oxygen, the zinc ion simultaneously increases the
electrophilicity of the carbonyl carbon atom of the scissile
amide bond in the bound collagen substrate.[12] Co-crystal
structures of collagenase H (ColH) and collagenase G (ColG)
from C. histolyticum with a selective and an unselective binder,
respectively, are available (PDB IDs: ColH with selective
inhibitor: 5O7E;[13] ColG with unselective inhibitor: 2Y6I[11]).
Clostridial collagenases represent “true” collagenases, that is,
they are collagen-specific and can degrade collagen in its native
triple-helical structure. This cleavage can occur at multiple sites,
thus generating small peptide fragments.[7,8a] In contrast, human
matrix metalloproteases (MMPs), that also include “true”
collagenases, are only able to cleave collagen at one site.[14]
After cleavage, the collagen fragments then have to undergo
further hydrolytic steps catalysed by different enzymes.
Besides the crucial role of clostridial collagenases in disease
development, their extracellular localisation[7] makes them
highly attractive drug targets. The penetration of the bacterial
cell wall often represents a major challenge for antibacterial
drug development,[15] but can thus be avoided in this case.
Naturally occurring collagenase-inhibiting coumarin derivatives
(e.g., 1, Figure 1) were found in extracts of Viola yedoensis.[9a]
Supuran and co-workers have made major contributions to the
emerging field of synthetic inhibitors of bacterial collagenases.
They have prepared and studied a variety of compounds that
mimic the natural substrate with an amide backbone and bind
strongly to the active site via a zinc-binding group (ZBG). The
latter coordinates to the zinc ion and displaces the essential
water molecule from the active site. The inhibitors vary in their
different ZBG, including 2-mercapto-substituted 1,3,4-thiadia-
zole (e.g., 2),[9b] carboxylate (e.g., 3),[9c] and hydroxamic acid
units (e.g., 4;[9d–f] Figure 1). However, all of these compounds
show one major drawback in that they are also strong inhibitors
of human MMPs due to highly homologous motifs in the active
sites of both enzyme families. These off-target effects severely
limit their potential to become suitable drug candidates.
More recently, we have reported the first selective inhibitor
5 of bacterial collagenases. “Hit” compound 5 contains a
thiocarbamate unit as a hydrolytically cleavable prodrug moiety
of the thiol 5a, which then strongly binds to the zinc ion and
therefore inhibits ColH in the low-nanomolar range
(Scheme 1).[13] This compound was also co-crystallised with the
target enzyme, revealing the exact binding mode in the non-
primed binding region. The interactions with the non-primed
edge strand, whose conformation is conserved and distinct for
clostridial collagenases, provide the high selectivity towards
various bacterial collagenases, including ColH and ColG from C.
histolyticum, ColT from C. tetani, and ColQ1 from Bacillus cereus,
over the unwanted inhibition of human MMPs.[13]
Very recently, we demonstrated that the linker unit in
structures of type 5a, that is, the motif connecting the aromatic
moiety and the thiol ZBG, can be varied. Thus, cyclisation to a
Figure 1. Structural diversity of selected previously reported ColH inhibitors with the zinc-binding groups highlighted in grey.[9]
Scheme 1. Structures of the previously identified “hit” ColH inhibitor 5, its
active thiol form 5a (after prodrug cleavage) and previously reported amide
analogue 6. General structure 7 of the novel potential collagenase inhibitors




1258ChemMedChem 2021, 16, 1257–1267 www.chemmedchem.org © 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH
Wiley VCH Dienstag, 13.04.2021
2108 / 195838 [S. 1258/1267] 1
succinimide is tolerated with a moderate loss of activity if the
thiol is kept in its relative position.[16] This, however, indicated
that inhibitor 5a can be further varied and optimised. One
obvious objective of such an optimisation process would be the
replacement of the ZBG. Even though there are thiol-containing
drugs in clinical use,[17a,b] thiols generally suffer from their
limited stability, mainly due to oxidative disulfide formation
that often leads to rapid inactivation.[17c] Therefore, a replace-
ment of the thiol with a different ZBG would be highly useful,
even if it might potentially lead to some loss of inhibitory
activity. Our goal was to retain the high selectivity of 5a for the
inhibition of bacterial collagenases vs. human off-targets.
Hence, the N-arylacetamide core structure was kept intact and
only the thiol moiety as the metal-binding group was
exchanged for various other ZBGs. Among the significant
number of zinc-binding units described in the literature,[18] we
decided to focus on sterically smaller motifs in order to retain
the previously identified binding mode.[13]
An amide 6 as a stable analogue of the thiocarbamate
structure of prodrug 5 (Scheme 1) has already been reported by
us.[13] Amide 6 had the same length as the thiocarbamate 5.
However, it was more than 400-fold less potent as a ColH
inhibitor. This result suggested to us that the overall length of 6
might not fit into the ColH active site, as the (shorter) thiol 5a
(and not thiocarbamate 5) was the actual zinc-binding inhibitor.
This consideration has significantly influenced our design of the
novel series 7 of potential ColH inhibitors described herein
(Scheme 1). Thus, most of the new target compounds contained
only one methylene unit to connect the amide carbonyl of the
core structure and the ZBG (in analogy to 5a). In this work, we
therefore report the synthesis and biological evaluation of 16
novel analogues of 5a with alternative, more stable ZBGs
attached to the core structure (general structure 7, Scheme 1).
Results and Discussion
Chemistry
As a first set of target compounds, we prepared new analogues
8–11 with amide (8), carboxylate (9, 10) and hydroxamate (11)
units as potential ZBG (Scheme 2, see also Table 1). Succinic
acid derivative 10 is a notable exception to the aforementioned
design principle (cf. general structure 7; Scheme 1) as it was the
higher homologue of malonic acid derivative 9 and the acid
Scheme 2. Synthesis of target compounds 8–11.
Table 1. In vitro inhibitory activities of all synthesised target compounds as well as reference compounds 5a and 6 against ColH.
Cpd. R1 R2 IC50 [μm] Cpd. R
1 R2 IC50 [μm] Cpd. R
1 R2 IC50 [μm]
5a Ac 0.017�0.002[13] 14 Ac >500 20 Ac >500
6 H >500[13] 15 Ac 448�33 23 Ac >500
8 H >500 16 Ac >500 24 Ac >500
9 H >500 17 Ac >500 25 Ac >500
10 H >500 18 Ac >500 26 Ac 7�1




1259ChemMedChem 2021, 16, 1257–1267 www.chemmedchem.org © 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH
Wiley VCH Dienstag, 13.04.2021
2108 / 195838 [S. 1259/1267] 1
derivative of amide 6, thus having one extra methylene unit to
connect the ZBG to the core structure.
Target compounds 8–11 were obtained via acylation of
aniline to give methyl esters 12 and 13 as intermediates in 62
and 98% yield, respectively. Subsequently, 12 was treated with
ammonia, potassium hydroxide or hydroxylamine to furnish 8,
9 and 11, respectively, in 27 to 83% yield. Ester saponification
of 13 afforded 10 in 65% yield (Scheme 2).
The zinc ion in the active site of ColH is complexed by two
histidine residues.[5a,11,13] Therefore, azole compounds 14–20
(Scheme 3, see also Table 1) were synthesised to mimic the
imidazole moiety of histidine. Triazole derivative 14 was
prepared in the following manner. Acylation of p-aminoaceto-
phenone with chloroacetyl chloride gave alkyl chloride 21 in
98% yield, and alkylation of 1,2,3-triazole with 21 furnished 14
in 25% yield. In order to obtain an alkylating agent with higher
reactivity, 21 was converted into alkyl iodide 22 in a Finkelstein
reaction (91% yield). Iodide 22 was then used for the alkylation
of other azoles, affording target compounds 15–18 in 32–65%
yield. Amide coupling of p-aminoacetophenone and cyano-
acetic acid gave nitrile intermediate 23 in 57% yield, which was
transformed into the target tetrazole 19 by zinc-catalysed
cycloaddition with sodium azide (33% yield). Imidazole-derived
analogue 20 was synthesised in one step (by amide coupling of
p-aminoacetophenone) in 39% yield (Scheme 3).
In order to exploit the potential of electrostatic interactions,
negatively charged ZBGs were also explored. Hence, target
compounds 24 (with a sulfonate unit as ZBG), 25 (phosphinate),
and 26 (phosphonate) were synthesised using the previously
employed alkyl chloride intermediate 21 (Scheme 4). Sulfonate
24 was obtained by alkylation of sulfite in 70% yield. Both
phosphinate 25 and phosphonate 26 were prepared in two
steps each, with the first step being a Michaelis–Arbuzov
reaction to give ethyl esters 27 and 28 in 75 and 89% yield,
respectively. This was followed by silyl-mediated cleavage of
the ethyl ester to afford (after ion exchange) highly pure
sodium salts 25 and 26 in yields of 44 and 60%, respectively.
In vitro inhibition of ColH
All synthesised target compounds were tested in a previously
described FRET-based in vitro assay for ColH inhibition, using a
custom-made quenched fluorescent peptide as substrate.[13]
The inhibitory activities (IC50 values) were obtained from steady-
state kinetics. Varying concentrations of the compounds were
preincubated with the peptidase domain of ColH (10 nm) for
1 h before the reactions were started by the addition of the
peptide substrate. IC50 values were determined by nonlinear
regression analysis and are listed in Table 1.
Interestingly, only two out of the 16 tested compounds with
various zinc-binding groups showed notable inhibitory activity
against ColH. These were tetrazole derivative 19 (IC50=22 μm)
and phosphonate 26 (IC50=7 μm). However, both compounds
were considerably weaker inhibitors of ColH than thiol 5a
(IC50=17 nm). As 26 was about three times more active than
19, it was decided to further investigate phosphonate 26 for
other biological properties in order to elucidate if it might be a
suitable alternative to 5a, in spite of its decreased inhibitory
potency towards the target collagenase ColH.
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Selectivity over potential human off-targets
Inhibitors of bacterial collagenases might potentially also bind
to human zinc-dependent enzymes as “off-targets”, even
though the results obtained with thiocarbamate 5 had demon-
strated that pronounced selectivity can be achieved (see
above).[13] We have therefore investigated if phosphonate 26 (in
comparison to thiol 5a as the active form of 5) inhibited a
selection of such zinc-dependent human off-targets. Our goal
was to at least retain the selectivity of “hit” compound 5 when
the ZBG is changed. The human enzymes chosen for this study
were six representatives of the MMP family, histone deacety-
lases 3 (HDAC-3) and 8 (HDAC-8), and the tumour necrosis
factor α (TNF-α) converting enzyme (TACE, also known as
ADAM-17). It should be noted that 5 had previously only been
tested for the unwanted inhibition of MMPs.[13]
Inhibitory activities of both 5a and novel ColH inhibitor 26
against this panel of potential human off-targets are provided
in Table 2 (as percentage inhibition at a fixed concentration of
100 μm). Against the six selected MMP enzymes, both ColH
inhibitors showed no notable to very moderate inhibition at
this rather high concentration. An exception was the inhibition
of MMP-8 (36% @100 μm) and MMP-14 (47% @100 μm),
respectively, by phosphonate 26. In contrast, both enzymes
were not inhibited by thiol 5a.[13] However, this implies that the
in vitro inhibitory activities of 26 towards these two representa-
tives of the MMP family were still more than one order of
magnitude lower than towards ColH as its bacterial target.
Overall, the rather limited inhibition of MMPs as human off-
targets by 26 confirmed our initial design principle to retain the
aromatic anilide core structure that had been shown to be
crucial for the selectivity of 5/5a.[13]
As noted, the other potential human off-targets investigated
in this context were two representatives of the HDAC family
and TACE. Regarding the unwanted inhibition of these three
enzymes, phosphonate 26 was superior to thiol 5a throughout
(Table 2). Thus, thiol 5a showed significantly higher inhibition
of the two HDAC tested (~50% inhibition with 5a vs. maximum
~10% with 26) and in particular of TACE (~80% with 5a vs.
~20% with 26). The unwanted inhibition of TACE would lead to
a decreased release of TNF-α, hence causing a reduced immune
response of the host[19] and thereby providing the bacteria with
a higher chance to establish a critical infection.[20] The absence
of notable HDAC and TACE inhibition for 26 represents a major
advantage of this novel phosphonate-derived ColH inhibitor.
Cytotoxicity against human cells
The new ColH inhibitor 26 was also investigated for potential
cytotoxic effects against three representative human cell lines,
that is, HepG2, HEK293, and A549 cells. Within the experimental
error, 26 showed a comparable or even slightly lower decrease
of cell viability (as an indicator of toxicity) than the previous
“hit” compound 5a in all investigated cell lines at 100 μm
compound concentration (Table 3). As a reference compound,
the approved antibiotic rifampicin (that is clinically used in the
long-term therapy of tuberculosis[21]) was also studied. Rifampi-
cin showed a comparable decrease of cell viability as both
tested ColH inhibitors 26 and 5a at an identical concentration
(100 μm). As further references and also as positive controls, the
chemotherapeutic agents doxorubicin[22a] and epirubicin[22b]
were employed and were found to be notably toxic at a 100-
fold lower concentration (i. e., 1 μm) in all three cell lines. In
turn, it can be concluded that even a 100-fold higher
concentration of 26 might be tolerated based on these
cytotoxicity studies.
Toxicity in a zebrafish model
In order to determine the toxicity of ColH inhibitors 26 and 5a
in an in vivo setting, a zebrafish larvae toxicity assay was
performed. Zebrafish are very small and almost transparent
organisms. They can be cultured in small volumes of media,
leading to very small amounts of compounds being needed for
testing. Furthermore, zebrafish develop their organ systems,
which show high similarity to the mammalian cardiovascular,
nervous, and digestive systems,[23a,b] in less than one week,[23a,c,d]
thus making the experiments fast and relatively inexpensive.
Using this assay, we aimed to determine the maximally
tolerated dose (MTD) at which no toxic effects of the
compounds were observed. It was found that both phospho-
nate 26 and thiol reference 5a showed no toxic effects at
concentrations up to 100 μm.Table 2. In vitro inhibitory activities of novel ColH inhibitor 26 (ZBG=
phosphonate) and reference compound 5a (ZBG= thiol) against a panel of
potential human off-targets.
Human enzyme Inhibition [%] at 100 μm compound[a]










[a] Means of at least two independent measurements, 10 nm enzyme
concentration. [b] n.i.=no inhibition (<10%).
Table 3. Cytotoxicity (as decrease of cell viability) of ColH inhibitors 26
(ZBG=phosphonate) and 5a (ZBG= thiol) as well as of three reference
compounds against three human cell lines.
Compound c [μm] Decrease of viability [%] after 48 h[a]
HepG2 HEK293 A549
5a (thiol) 100 15�9 53�0 18�12
26 (phosphonate) 100 8�10 32�4 20�2
rifampicin 100 33�13 29�13 9�13
doxorubicin 1 57�14 47�9 53�13
epirubicin 1 68�10 49�11 56�12
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Ex vivo pig skin degradation assay
To investigate the activity of collagenase inhibitors on tissue in
a more complex experimental setting, an ex vivo pig skin
degradation assay using purified ColQ1 from B. cereus has
recently been developed.[16] The degradation of collagen in this
mammalian tissue was measured as a rate of hydroxyproline
(Hyp) release. This assay had previously been used to demon-
strate the efficacy of succinimide 29 (Figure 2) as an inhibitor of
bacterial collagenase activity.[16] Succinimide derivative 29 had
an IC50 value of 0.06�0.01 μm against ColH in vitro, which
indicates that it is ca. 100-fold more potent than phosphonate
26. Towards ColQ1 (at a fixed inhibitor concentration of
100 μm), 29 had shown complete (100�2%) inhibition, which
corresponded to an IC50 value significantly below 100 μm.
[16]
Using the same in vitro assay, novel phosphonate 26 had an IC50
value of 183�7 μm. However, in the ex vivo assay, 26 reduced
the formation of Hyp to 75% of the Hyp production of the
control at a concentration of 100 μm, which is nearly identical
to the potency of 29 (Figure 3).
Overall, succinimide 29 showed a stronger reduction of Hyp
formation at elevated concentrations than phosphonate 26, in
particular at 300 and 400 μm, respectively (Figure 3). However,
this difference in potency was far less than what was expected
based on the significant difference of the aforementioned
in vitro activities (IC50 values). It should also be noted that
succinimide 29 appears to reach a “plateau” in activity between
about 300 and 400 μm while phosphonate 26 had a nearly
linear correlation of concentration and activity. This “plateau” in
the activity of 29 might eventually result from disulfide
formation at higher concentrations. This again highlights the
benefit of employing an oxidation-resistant ZBG (as in 26) to
provide air-stable alternatives to thiol-derived inhibitors.
Conclusions
In summary, we herein report the exchange of the thiol ZBG of
previously published selective ColH inhibitors with more stable
ZBGs, with the selectivity of the thiol-based “hit” compound 5a
being retained. Thus, the structure of 5a was varied to furnish
phosphonate derivative 26. In contrast to the thiol group in 5a,
the phosphonate as a ZBG in 26 is not prone to oxidation or
degradation. Novel inhibitor 26 still showed reasonably potent
(i. e., micromolar) inhibition of the clostridial collagenase ColH,
while apparently retaining the binding mode of 5a and
therefore its remarkable selectivity over potential human off-
targets such as MMPs. In comparison to 5a, we observed a
better selectivity of 26 over other human off-targets (HDAC and
TACE), suggesting it might be an improved hit structure for
further development. Inhibitor 26 showed no indication of
major toxicity in three different human cell lines as well as high
tolerance in an in vivo zebrafish toxicity assay. Furthermore, we
demonstrated the efficacy of 26 not only in an in vitro enzyme
assay for collagenase activity, but also in a more complex ex
vivo pig skin degradation assay. The results from this assay
highlight the potency of 26 and the relevance of a stable (non-
thiol) ZBG for biological activity in a complex biological setting.
Overall, 26 should therefore be considered as a new improved
hit structure for the development of potent inhibitors of
bacterial collagenases that will now undergo further optimisa-
tion in our laboratories.
Experimental Section
General methods: All chemicals, starting materials and reagents
were purchased from standard suppliers and used without further
purification. Air- and/or water-sensitive reactions were carried out
under nitrogen atmosphere with anhydrous solvents. Anhydrous
solvents were obtained in the following manner: THF, DMF and
CH2Cl2 were dried with a solvent purification system (MBRAUN MB
SPS 800). All other solvents were of technical quality and distilled
prior to use, and deionised water was used throughout. Reactions
were monitored by TLC on aluminium plates precoated with silica
gel 60 F254 (VWR). Visualisation of the spots was carried out using
UV light (254 nm) and/or staining under heating (VSS stain: 4 g
vanillin, 25 mL conc. H2SO4, 80 mL AcOH, 680 mL MeOH; CAM stain:
12 g ammonium molybdate, 0.5 g ceric ammonium molybdate,
235 mL H2O, 15 mL conc. H2SO4; ninhydrin stain: 1.5 g ninhydrin,
100 mL n-butanol, 3.0 mL AcOH). Rf values are given to the nearest
0.05. Column chromatography was carried out on silica gel 60 (40–
63 μm, 230–400 mesh ASTM, VWR) under flash conditions. Prepara-
tive centrifugal TLC was performed on a ChromatotronTM 7924T (T-
Squared Technology) using glass plates coated with silica gel 60
PF254 containing a fluorescent indicator (VWR, thickness depending
on the amount of crude material to be separated, for 50–500 mg:
1 mm layer). Ion-exchange chromatography was carried out using
DOWEX™ 50WX8 resin (200–400 mesh, VWR) in the Na+ form.
Semipreparative HPLC was performed on a VWR-Hitachi system
equipped with an L-2300 pump, an L-2200 autosampler, an L-2455
Figure 2. Structures and in vitro potencies for collagenase inhibition of
compounds 26 and 29.[16]
Figure 3. Ex vivo pig skin degradation assay: hydroxyproline release after
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diode array detector (DAD) and a LichroCartTM PurospherTM RP18e
column (5 μm, 10×250 mm, VWR). NMR spectra were recorded
using the following Bruker NMR spectrometers: for 1H NMR spectra
at 500 MHz and 13C NMR spectra at 126 MHz: Avance™ 500; for 31P
NMR spectra at 203 MHz: Avance™ 500. For the assignment of
signals, 1H,1H COSY, 1H,13C HSQC and 1H,13C HMBC spectra were
used. All 13C and 31P NMR spectra are 1H-decoupled. All spectra
were recorded at room temperature if not indicated otherwise and
were referenced internally to solvent residual signals wherever
possible. Chemical shifts (δ) are quoted in ppm and coupling
constants (J) are reported in Hz. Low-resolution mass spectra were
recorded on a liquid chromatography-coupled mass spectrometer
(LC–MS) Surveyor MSQ Plus from Finnigan. For the LC separation
prior to detection, a NucleodurTM 100–5 C18 column (5 μm, 3×
125 mm) was used. High-resolution mass spectra were recorded on
a Thermo Scientific Q Exactive Orbitrap mass spectrometer with ESI
ionisation mode coupled with an Ultimate 3000 HPLC system by
Thermo Scientific, equipped with a Thermo AccucoreTM phenyl-X
column (2.1 μm, 3×100 mm). Melting points (mp) were measured
on a melting point apparatus SMP3 (Stuart Scientific) and were not
corrected.
General procedure (GP1) for the synthesis of azole derivatives:
Alkyl iodide 22 (1.0 equiv), K2CO3 (1.1 equiv), and the respective
azole (1.1 equiv) were suspended in acetone (20 mL, ~25 mm) and
stirred at 70 °C overnight (15–20 h). EtOAc (200 mL) was added, and
the organic layer was washed with water (3×30 mL) and brine
(50 mL) and dried over Na2SO4. The solvent was evaporated under
reduced pressure and the resultant crude product was purified by
column chromatography to give the respective azole derivative.
General procedure (GP2) for the cleavage of ethyl esters: The
respective ethyl ester (1.0 equiv) was dissolved in CH2Cl2 (10 mL).
TMSBr (5.0 equiv) was added dropwise over 10 min, and the
reaction was stirred at RT overnight (15–20 h). MeOH (10 mL) was
then added, and the mixture was stirred for 1–2 h. The solvent was
evaporated under reduced pressure, the resultant crude product
was purified by HPLC and the obtained product was converted into
its Na+ form by ion-exchange column chromatography to give the
respective title compound.
N1-Phenylmalonamide (8): Methyl ester 12 (49 mg, 0.25 mmol) was
dissolved in MeOH (6 mL). NH3 solution (33%, 3 mL) was added,
and the reaction mixture was stirred at RT overnight. The solvent
was evaporated under reduced pressure and the resultant crude
product was purified by column chromatography (CH2Cl2/MeOH
100:0!95 :5) to give 8 as a white solid (37 mg, 83%). 1H NMR
(500 MHz, [D6]DMSO): δ=10.07 (s, 1H, Ph-NH), 7.58 (d, J=7.6 Hz,
2H, 2’-H, 6’-H), 7.51 (br, 1H, NH2-a), 7.30 (t, J=7.9 Hz, 2H, 3’-H, 5’-H),
7.11 (br, 1H, NH2-b), 7.04 (t, J=7.4 Hz, 1H, 4’-H), 3.21 (s, 2H, 2-H)
ppm. 13C NMR (126 MHz, [D6]DMSO): δ=168.68 (C-1 or C-3), 165.74
(C-1 or C-3), 138.96 (C-1’), 128.71 (C-3’, C-5’), 123.27 (C-4’), 119.02
(C-2’, C-6’), 44.50 (C-2) ppm. HRMS (ESI): calcd. for C9H11N2O2 [M+
H]+ 179.0815, found 179.0813. TLC (petroleum ether/EtOAc 1 :1):
Rf=0.10.
3-Oxo-3-(phenylamino)propanoic acid (9): Methyl ester 12
(102 mg, 0.528 mmol) was dissolved in MeOH (5 mL). KOH solution
(50 g/L, 1.2 mL) was added, and the reaction mixture was stirred at
35 °C for 4 h. It was then acidified with HCl, and EtOAc (200 mL)
was added. The organic layer was washed with HCl (2 m, 4×40 mL)
and brine (50 mL) and then dried over Na2SO4. The solvent was
evaporated under reduced pressure, and the resultant crude
product was purified by column chromatography (CH2Cl2/MeOH/
HCOOH 95 :4 : 1) to give 9 as a white solid (70 mg, 74%). 1H NMR
(500 MHz, [D6]DMSO): δ=12.68 (br, 1H, COOH), 10.13 (s, 1H, NH),
7.57 (d, J=7.6 Hz, 2H, 2’-H, 6’-H), 7.31 (t, J=7.9 Hz, 2H, 3’-H, 5’-H),
7.05 (t, J=7.4 Hz, 1H, 4’-H), 3.34 (s, 2H, 2-H) ppm. 13C NMR
(126 MHz, [D6]DMSO): δ=169.28 (C-1 or C-3), 164.57 (C-1 or C-3),
138.95 (C-1’), 128.76 (C-3’, C-5’), 123.38 (C-4’), 119.01 (C-2’, C-6’),
43.99 (C-2) ppm. HRMS (ESI): calcd. for C9H10NO3 [M+H]
+ 180.0655,
found 180.0654. TLC (petroleum ether/EtOAc/HCOOH 49 :49 :2): Rf=
0.20.
4-Oxo-4-(phenylamino)butanoic acid (10): Methyl ester 13
(204 mg, 0.985 mmol) was dissolved in MeOH (4 mL). KOH solution
(50 g/L, 2.2 mL) was added, and the reaction mixture was stirred at
35 °C for 4 h. It was then acidified with HCl and EtOAc (200 mL) was
added. The organic layer was washed with HCl (2 m, 4×40 mL) and
brine (50 mL) and then dried over Na2SO4. The solvent was
evaporated under reduced pressure, and the resultant crude
product was purified by column chromatography (petroleum ether/
EtOAc/HCOOH 70 :29 :1) to give 10 as a white solid (124 mg, 65%).
1H NMR (500 MHz, [D6]DMSO): δ=12.20 (br, 1H, COOH), 9.94 (br,
1H, NH), 7.57 (d, J=7.6 Hz, 2H, 2’-H, 6’-H), 7.28 (t, J=7.9 Hz, 2H, 3’-
H, 5’-H), 7.01 (t, J=7.4 Hz, 1H, 4’-H), 2.56-2.50 (m, 4H, 2-H, 3-H) ppm.
13C NMR (126 MHz, [D6]DMSO): δ=173.83 (C-1 or C-4), 170.06 (C-1
or C-4), 139.30 (C-1’), 128.65 (C-3’, C-5’), 122.88 (C-4’), 118.87 (C-2’,
C-6’), 31.04 (C-2 or C-3), 28.82 (C-2 or C-3) ppm. HRMS (ESI): calcd.
for C10H12NO3 [M+H]
+ 194.0812, found 194.0810. TLC (petroleum
ether/EtOAc/HCOOH 49 :49 :2): Rf=0.25.
N1-Hydroxy-N3-phenylmalonamide (11): Hydroxylamine
hydrochloride (497 mg, 7.15 mmol), DIPEA (1.50 mL, 8.61 mmol)
and KCN (19 mg, 0.29 mmol) were dissolved in MeOH (5 mL), and
the mixture was heated to reflux. After 10 min, a solution of methyl
ester 12 (91 mg, 0.47 mmol) in MeOH (5 mL) was added, and the
reaction mixture was stirred under reflux overnight. It was then
concentrated under reduced pressure, acidified with HCl (1 m,
100 mL) and extracted with EtOAc (5×50 mL). The combined
organics were dried over Na2SO4, and the solvent was evaporated
under reduced pressure. The resultant crude product was purified
by HPLC (water+0.1% TFA, MeCN+0.1% TFA, 95 :5!0 :100) to
give 11 as a slightly orange solid (25 mg, 27%). 1H NMR (500 MHz,
[D6]DMSO): δ=10.61 (s, 1H, NHOH), 10.10 (s, 1H, Ph-NH), 8.96 (br,
1H, NHOH), 7.57 (d, J=7.8 Hz, 2H, 2’-H, 6’-H), 7.30 (t, J=7.8 Hz, 2H,
3’-H, 5’-H), 7.05 (t, J=7.3 Hz, 1H, 4’-H), 3.11 (s, 2H, 2-H) ppm. 13C
NMR (126 MHz, [D6]DMSO): δ=165.27 (C-1 or C-3), 163.48 (C-1 or C-
3), 138.93 (C-1’), 128.76 (C-3’, C-5’), 123.38 (C-4’), 119.07 (C-2’, C-6’),
42.03 (C-2) ppm. HRMS (ESI): calcd. for C9H9N2O3 [M  H]
  193.0619,
found: 193.0609. TLC (CH2Cl2/MeOH/HCOOH 90 :9 : 1): Rf=0.15.
Methyl 3-oxo-3-(phenylamino)propanoate (12): Aniline (400 μL,
4.39 mmol) and NEt3 (1.20 mL, 8.61 mmol) were dissolved in CH2Cl2
(10 mL) and cooled to 0 °C. Methyl malonyl chloride (500 μL,
5.24 mmol) was added dropwise over 15 min, and the reaction
mixture was stirred at 0 °C for 3 h. The reaction was quenched with
cold water (15 mL), and the mixture was diluted with CH2Cl2. The
organic layer was washed with sat. NaHCO3 solution (5×40 mL) and
dried over Na2SO4. The solvent was evaporated under reduced
pressure, and the resultant crude product was purified by column
chromatography (CH2Cl2) to give 12 as a slightly orange solid
(523 mg, 62%). 1H NMR (500 MHz, CDCl3): δ=9.15 (br, 1H, NH), 7.55
(d, J=8.1 Hz, 2H, 2’-H, 6’-H), 7.33 (t, J=7.9 Hz, 2H, 3’-H, 5’-H), 7.13 (t,
J=7.4 Hz, 1H, 4’-H), 3.80 (s, 3H, OCH3), 3.49 (s, 2H, 2-H) ppm.
13C
NMR (126 MHz, CDCl3): δ=170.58 (C-1 or C-3), 162.82 (C-1 or C-3),
137.54 (C-1’), 129.15 (C-3’, C-5’), 124.76 (C-4’), 120.25 (C-2’, C-6’),
52.82 (OCH3), 41.45 (C-2) ppm. MS (ESI): m/z=216.0 [M+Na]
+. TLC
(petroleum ether/EtOAc 7 :3): Rf=0.10.
Methyl 4-oxo-4-(phenylamino)butanoate (13): Aniline (100 μL,
1.10 mmol) and NEt3 (300 μL, 2.15 mmol) were dissolved in CH2Cl2
(5 mL) and cooled to 0 °C. Methyl succinyl chloride (170 μL,
1.38 mmol) was added dropwise over 10 min, and the reaction
mixture was stirred at 0 °C for 3.5 h. The reaction was quenched
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The organic layer was washed with sat. NaHCO3 solution (4×30 mL)
and dried over Na2SO4. The solvent was evaporated under reduced
pressure and the resultant crude product was purified by
centrifugal TLC (CH2Cl2) to give 13 as a white solid (222 mg, 98%).
1H NMR (500 MHz, CDCl3): δ=7.71 (br, 1H, NH), 7.50 (d, J=7.9 Hz,
2H, 2’-H, 6’-H), 7.29 (t, J=7.9 Hz, 2H, 3’-H, 5’-H), 7.09 (t, J=7.4 Hz,
1H, 4’-H), 3.70 (s, 3H, OCH3), 2.75 (t, J=6.5 Hz, 2H, 2-H or 3-H), 2.66
(t, J=6.5 Hz, 2H, 2-H or 3-H) ppm. 13C NMR (126 MHz, CDCl3): δ=
173.78 (C-1 or C-4), 169.84 (C-1 or C-4), 137.97 (C-1’), 129.07 (C-3’, C-
5’), 124.35 (C-4’), 119.90 (C-2’, C-6’), 52.12 (OCH3), 32.20 (C-2 or C-3),
29.36 (C-2 or C-3) ppm. HRMS (ESI): calcd. for C11H14NO3 [M+H]
+
208.0968, found 208.0961. TLC (petroleum ether/EtOAc 7 :3): Rf=
0.10.
N-(4-Acetylphenyl)-2-(1H-1,2,3-triazol-1-yl)acetamide (14): Alkyl
chloride 21 (60 mg, 0.28 mmol), NEt3 (90 μL, 0.65 mmol) and 1H-
1,2,3-triazole (20 μL, 0.34 mmol) were dissolved in DMF (10 mL) and
stirred at RT for 8 d. EtOAc (250 mL) was added, and the organic
layer was washed with water (5×30 mL) and brine (30 mL) and
then dried over Na2SO4. The solvent was evaporated under reduced
pressure, and the resultant crude product was purified by column
chromatography (CH2Cl2/MeOH 99 :1) to give 14 as a white solid
(17 mg, 25%). 1H NMR (500 MHz, [D6]DMSO): δ=10.83 (s, 1H, NH),
8.17 (d, J=0.9 Hz, 1H, 5’’-H), 7.96 (d, J=8.8 Hz, 2H, 3’-H, 5’-H), 7.77
(d, J=0.8 Hz, 1H, 4’’-H), 7.72 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 5.41 (s, 2H,
2-H), 2.53 (s, 3H, acetyl-CH3) ppm.
13C NMR (126 MHz, [D6]DMSO):
δ=196.52 (acetyl-C=O), 164.96 (C-1), 142.69 (C-1’), 133.15 (C-4’’),
132.15 (C-4’), 129.61 (C-3’, C-5’), 126.55 (C-5’’), 118.53 (C-2’, C-6’),
52.04 (C-2), 26.45 (acetyl-CH3) ppm. MS (ESI): m/z=245.0 [M+H]
+.
HRMS (ESI): calcd. for C12H13N4O2 [M+H]
+ 245.1033, found
245.1030. TLC (CH2Cl2/MeOH 95 :5): Rf=0.15.
N-(4-Acetylphenyl)-2-(1H-imidazol-1-yl)acetamide (15): General
procedure GP1 with 1H-imidazole (41 mg, 0.60 mmol) and alkyl
iodide 22 (156 mg, 0.515 mmol) to give 15 as a white solid (47 mg,
38%). 1H NMR (500 MHz, [D6]DMSO): δ=10.65 (s, 1H, NH), 7.95 (d,
J=8.8 Hz, 2H, 3’-H, 5’-H), 7.72 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 7.64 (s,
1H, 2’’-H), 7.17 (t, J=1.9 Hz, 1H, 5’’-H), 6.90 (t, J=0.9 Hz, 1H, 4’’-H),
4.96 (s, 2H, 2-H), 2.53 (s, 3H, acetyl-CH3) ppm.
13C NMR (126 MHz,
[D6]DMSO): δ=196.50 (acetyl-C=O), 166.43 (C-1), 142.93 (C-1’),
138.35 (C-2’’), 131.93 (C-4’), 129.59 (C-3’, C-5’), 127.92 (C-4’’), 120.76
(C-5’’), 118.39 (C-2’, C-6’), 49.18 (C-2), 26.43 (acetyl-CH3) ppm. HRMS
(ESI): calcd. for C13H14N3O2 [M+H]
+ 244.1081, found 244.1078. TLC
(CH2Cl2/MeOH 9 :1): Rf=0.20.
N-(4-Acetylphenyl)-2-(1H-1,2,4-triazol-1-yl)acetamide (16): General
procedure GP1 with 1H-1,2,4-triazol (46 mg, 0.67 mmol) and alkyl
iodide 22 (165 mg, 0.545 mmol) to give 16 as a slightly orange solid
(87 mg, 65%). 1H NMR (500 MHz, [D6]DMSO): δ=10.76 (s, 1H, NH),
8.56 (s, 1H, 5’’-H), 8.01 (s, 1H, 3’’-H), 7.95 (d, J=8.8 Hz, 2H, 3’-H, 5’-
H), 7.71 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 5.19 (s, 2H, 2-H), 2.53 (s, 3H,
acetyl-CH3) ppm.
13C NMR (126 MHz, [D6]DMSO): δ=196.58 (acetyl-
C=O), 165.26 (C-1), 151.47 (C-3’’), 145.69 (C-5’’), 142.73 (C-1’), 132.16
(C-4’), 129.66 (C-3’, C-5’), 118.55 (C-2’, C-6’), 51.85 (C-2), 26.51
(acetyl-CH3) ppm. MS (ESI): m/z=245.0 [M+H]
+. HRMS (ESI): calcd.
for C12H13N4O2 [M+H]
+ 245.1033, found 245.1030. TLC (CH2Cl2/
MeOH 95 :5): Rf=0.10.
N-(4-Acetylphenyl)-2-(1H-tetrazol-1-yl)acetamide (17) and N-(4-
acetylphenyl)-2-(2H-tetrazol-2-yl)acetamide (18): General proce-
dure GP1 with 1H-tetrazole (27 mg, 0.39 mmol) and alkyl iodide 22
(101 mg, 0.333 mmol) to give 17 as a white solid (28 mg, 34%) and
18 as a white solid (26 mg, 32%). 17: 1H NMR (500 MHz, [D6]DMSO):
δ=10.90 (s, 1H, NH), 9.43 (s, 1H, 5’’-H), 7.96 (d, J=8.8 Hz, 2H, 3’-H,
5’-H), 7.71 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 5.54 (s, 2H, 2-H), 2.53 (s, 3H,
acetyl-CH3) ppm.
13C NMR (126 MHz, [D6]DMSO): δ=196.55 (acetyl-
C=O), 164.14 (C-1), 145.26 (C-5’’), 142.50 (C-1’), 132.27 (C-4’), 129.64
(C-3’, C-5’), 118.59 (C-2’, C-6’), 50.14 (C-2), 26.46 (acetyl-CH3) ppm.
MS (ESI): m/z=246.0 [M+H]+, 268.0 [M+Na]+. HRMS (ESI): calcd.
for C11H13N5O2 [M+H]
+ 246.0986, found 246.0982. TLC (CH2Cl2/
MeOH 95 :5): Rf=0.25. 18: 1H NMR (500 MHz, [D6]DMSO): δ=10.95
(s, 1H, NH), 9.05 (s, 1H, 5’’-H), 7.96 (d, J=8.8 Hz, 2H, 3’-H, 5’-H), 7.70
(d, J=8.8 Hz, 2H, 2’-H, 6’-H), 5.78 (s, 2H, 2-H), 2.53 (s, 3H, acetyl-CH3)
ppm. 13C NMR (126 MHz, [D6]DMSO): δ=196.53 (acetyl-C=O), 163.52
(C-1), 153.42 (C-5’’), 142.40 (C-1’), 132.34 (C-4’), 129.61 (C-3’, C-5’),
118.65 (C-2’, C-6’), 55.05 (C-2), 26.46 (acetyl-CH3) ppm. HRMS (ESI):
calcd. for C11H12N5O2 [M+H]
+ 246.0986, found 246.0984. TLC
(CH2Cl2/MeOH 95 :5): Rf=0.40.
N-(4-Acetylphenyl)-2-(2H-tetrazol-5-yl)acetamide (19): A suspen-
sion of nitrile 23 (102 mg, 0.505 mmol), NaN3 (159 mg, 2.45 mmol)
and ZnBr2 (100 mg, 0.444 mmol) in iPrOH/water (1 :3) was stirred
under reflux for 2 d. After cooling to RT, EtOAc (200 mL) was added,
and the organic layer was washed with HCl (0.2 m, 3×50 mL) and
brine (50 mL) and then dried over Na2SO4. The solvent was
evaporated under reduced pressure, and the resultant crude
product was purified by centrifugal TLC (CH2Cl2/MeOH 100:0!
90 :10) to give 19 as a white solid (41 mg, 33%). 1H NMR (500 MHz,
[D6]DMSO): δ=16.26 (br, 1H, 2’’-NH), 10.78 (s, 1H, NH(C=O)), 7.95 (d,
J=8.8 Hz, 2H, 3’-H, 5’-H), 7.72 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 4.20 (s,
2H, 2-H), 2.53 (s, 3H, acetyl-CH3) ppm.
13C NMR (126 MHz, [D6]
DMSO): δ=196.56 (acetyl-C=O), 165.73 (C-1), 150.82 (C-5’’, HMBC),
142.95 (C-1’), 132.11 (C-4’), 129.60 (C-3’, C-5’), 118.52 (C-2’, C-6’),
31.80 (C-2), 26.48 (acetyl-CH3) ppm. MS (ESI): m/z=246.0 [M+H]
+.
HRMS (ESI): calcd. for C11H12N5O2 [M+H]
+ 246.0986, found
246.0980. TLC (CH2Cl2/MeOH/HCOOH 94 :5 : 1): Rf=0.50.
N-(4-Acetylphenyl)-2-(1H-imidazol-4-yl)acetamide (20): 2-(1H-imi-
dazol-4-yl)acetic acid hydrochloride (180 mg, 1.11 mmol), HBTU
(430 mg, 1.13 mmol) and DIPEA (140 μL, 0.823 mmol) were dis-
solved in DMF (5 mL). After 5 min stirring at RT, p-aminoacetophe-
none (101 mg, 0.747 mmol) was added, and the reaction mixture
was stirred at RT for 27 h. EtOAc (200 mL) was added, and the
organic layer was washed with NaHCO3 solution (1.0 m, 3×50 mL)
and brine (50 mL) and then dried over Na2SO4. The solvent was
evaporated under reduced pressure, and the resultant crude
product was purified by column chromatography (CH2Cl2/MeOH/
NEt3 90 :5 : 5) to give 20 as a white solid (70 mg, 39%).
1H NMR
(500 MHz, [D6]DMSO): δ=11.95 (br, 1H, 1’’-NH), 10.44 (s, 1H,
NH(C=O)), 7.92 (d, J=8.8 Hz, 2H, 3’-H, 5’-H), 7.73 (d, J=8.8 Hz, 2H,
2’-H, 6’-H), 7.58 (d, J=1.0 Hz, 1H, imidazole-H), 6.94 (s, 1H,
imidazole-H), 3.61 (s, 2H, 2-H), 2.52 (s, 3H, acetyl-CH3) ppm.
13C NMR
(126 MHz, [D6]DMSO): δ=196.46 (acetyl-C=O), 169.29 (C-1), 143.57
(C-1’), 134.95 (imidazole-C), 131.60 (C-4’), 129.47 (C-3’, C-5’), 118.25
(C-2’, C-6’), 35.87 (C-2), 26.40 (acetyl-CH3) ppm (due to poor
relaxation, two imidazole-carbon nuclei could not be observed, but
the respective hydrogen nuclei were found in the 1H NMR
spectrum). HRMS (ESI): calcd. for C13H14N3O2 [M+H]
+ 244.1081,
found 244.1077. TLC (CH2Cl2/MeOH/NEt3 85 :10 :5): Rf=0.25.
N-(4-Acetylphenyl)-2-chloroacetamide (21): p-Aminoacetophe-
none (1.00 g, 7.41 mmol) and DIPEA (1.40 mL, 8.18 mmol) were
dissolved in THF (5 mL). Chloroacetyl chloride (650 μL, 8.16 mmol)
was added dropwise, and the reaction mixture was stirred at RT for
20 min. The reaction was quenched by addition of MeOH (15 mL).
The mixture was then diluted with EtOAc (200 mL), washed with
HCl (0.2 m, 3×30 mL) and sat. NaHCO3 solution (3×30 mL) and
then dried over Na2SO4. The solvent was evaporated under reduced
pressure to give 21 as a slightly green solid (1.54 g, 98%). 1H NMR
(500 MHz, CDCl3): δ=8.41 (s, 1H, NH), 7.98 (d, J=8.7 Hz, 2H, 3’-H, 5’-
H), 7.68 (d, J=8.7 Hz, 2H, 2’-H, 6’-H), 4.22 (s, 2H, 2-H), 2.59 (s, 3H,
acetyl-CH3) ppm.
13C NMR (126 MHz, CDCl3): δ=196.95 (acetyl-C=O),
164.14 (C-1), 141.00 (C-1’), 133.90 (C-4’), 129.89 (C-3’, C-5’), 119.39
(C-2’, C-6’), 42.99 (C-2), 26.61 (acetyl-CH3) ppm. HRMS (ESI): calcd.
for C10H11ClNO2 [M+H]
+ 212.0473, found 212.0466. TLC (CH2Cl2/
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N-(4-Acetylphenyl)-2-iodoacetamide (22): Alkyl chloride 21
(364 mg, 1.72 mmol) and KI (859 mg, 5.18 mmol) were dissolved in
acetone (20 mL), and the reaction mixture was stirred at RT for
15 h. EtOAc (200 mL) was added, the organic layer was washed
with NaHCO3 solution (0.5 m, 3×50 mL), HCl (0.5 m, 3×50 mL) and
brine (50 mL) and then dried over Na2SO4. The solvent was
evaporated under reduced pressure to give 22 as a slightly orange
solid (472 mg, 91%). 1H NMR (500 MHz, CDCl3+CD3OD): δ=7.91 (d,
J=9.0 Hz, 2H, 3’-H, 5’-H), 7.63 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 3.83 (s,
2H, 2-H), 2.55 (s, 3H, acetyl-CH3) ppm.
13C NMR (126 MHz, CDCl3+
CD3OD): δ=197.53 (acetyl-C=O), 166.56 (C-1), 142.42 (C-1’), 133.09
(C-4’), 129.78 (C-3’, C-5’), 119.04 (C-2’, C-6’), 26.50 (acetyl-CH3),
  0.71 (C-2) ppm. HRMS (ESI): calcd. for C10H11INO2 [M+H]
+
303.9829, found 303.9824. TLC (petroleum ether/EtOAc 7 :3): Rf=
0.15.
N-(4-Acetylphenyl)-2-cyanoacetamide (23): Cyanoacetic acid
(141 mg, 1.66 mmol), DIPEA (580 μL, 3.33 mmol) and EDC
hydrochloride (428 mg, 2.23 mmol) were dissolved in CH2Cl2
(10 mL) and the mixture was stirred at RT for 15 min. Then, p-
aminoacetophenone (205 mg, 1.52 mmol) was added, and the
reaction mixture was stirred at RT for 22 h. EtOAc (250 mL) was
added, the organic layer was washed with water (2×50 mL), HCl
(0.2 m, 1×50 mL) and brine (50 mL) and then dried over Na2SO4.
The solvent was evaporated under reduced pressure, and the
resultant crude product was purified by column chromatography
(CH2Cl2/MeOH 98 :2) to give 23 as a white solid (176 mg, 57%). 1H
NMR (500 MHz, [D6]DMSO): δ=10.62 (s, 1H, NH), 7.95 (d, J=8.8 Hz,
2H, 3’-H, 5’-H), 7.68 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 3.96 (s, 2H, 2-H),
2.53 (s, 3H, acetyl-CH3) ppm.
13C NMR (126 MHz, [D6]DMSO): δ=
196.53 (acetyl-C=O), 161.71 (C-1), 142.60 (C-1’), 132.25 (C-4’), 129.58
(C-3’, C-5’), 118.52 (C-2’, C-6’), 115.69 (CN), 27.01 (C-2), 26.46 (acetyl-
CH3) ppm. HRMS (ESI): calcd. for C11H11N2O2 [M+H]
+ 203.0815,
found 203.0813. TLC (CH2Cl2/MeOH 95 :5): Rf=0.35.
Sodium 2-((4-acetylphenyl)amino)-2-oxoethane-1-sulfonate (24):
To a suspension of alkyl chloride 21 (509 mg, 2.40 mmol) in EtOH
(6 mL), a solution of Na2SO3 (302 mg, 2.40 mmol) in water (6 mL)
was added. The reaction mixture was stirred under reflux for 4 h.
The formed precipitate was filtered off, washed with cold water and
dried to give 24 as a white solid (473 mg, 70%). 1H NMR (500 MHz,
[D6]DMSO): δ=10.31 (s, 1H, NH), 7.92 (d, J=8.8 Hz, 2H, 3’-H, 5’-H),
7.71 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 3.57 (s, 2H, 1-H), 2.52 (s, 3H, acetyl-
CH3) ppm.
13C NMR (126 MHz, [D6]DMSO): δ=196.49 (acetyl-C=O),
165.01 (C-2), 143.43 (C-1’), 131.58 (C-4’), 129.47 (C-3’, C-5’), 118.18
(C-2’, C-6’), 59.10 (C-1), 26.42 (acetyl-CH3) ppm. HRMS (ESI): calcd.
for C10H12NO5S [M(acid)+H]
+ 258.0431, found 258.0428. TLC
(CH2Cl2/MeOH 95 :5): Rf=0.00.
Sodium (2-((4-acetylphenyl)amino)-2-oxoethyl)(methyl)
phosphinate (25): General procedure GP2 with ethyl ester 27
(50 mg, 0.18 mmol) to give 25 as a white solid (23 mg, 44%). 1H
NMR (500 MHz, [D6]DMSO): δ=10.77 (s, 1H, NH), 7.87 (d, J=8.8 Hz,
2H, 3’-H, 5’-H), 7.71 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 2.96 (d, J=17.7 Hz,
2H, 1-H), 2.50 (br, 3H (under solvent signal), acetyl-CH3), 1.42 (d, J=
14.8 Hz, 3H, PCH3) ppm.
13C NMR (126 MHz, [D6]DMSO): δ=196.42
(acetyl-C=O), 166.00 (C-1), 143.69 (C-1’), 131.51 (C-4’), 129.37 (C-3’,
C-5’), 118.17 (C-2’, C-6’), 42.13 (d, JCP=78.7 Hz, C-1), 26.36 (acetyl-
CH3), 16.29 (d, JCP=97.7 Hz, PCH3) ppm.
31P NMR (162 MHz, [D6]
DMSO): δ=37.80 ppm. HRMS (ESI): calcd. for C11H15NO4P [M(acid)+
H]+ 256.0733, found: 256.0730. TLC (CH2Cl2/MeOH/HCOOH
85 :13 :2): Rf=0.05.
Disodium (2-((4-acetylphenyl)amino)-2-oxoethyl)phosphonate
(26): General procedure GP2 with ethyl ester 28 (182 mg,
0.581 mmol) to give 26 as a slightly orange solid (89 mg, 60%). 1H
NMR (500 MHz, CD3OD): δ=8.62 (d, J=8.8 Hz, 3’-H, 5’-H), 8.27 (d,
J=8.8 Hz, 2’-H, 6’-H), 3.64 (d, J=21.0 Hz, 1-H), 3.26 (s, 3H, acetyl-
CH3) ppm.
13C NMR (126 MHz, CD3OD): δ=213.57 (acetyl-C=O),
179.12 (C-2), 153.54 (C-1’), 143.67 (C-4’), 141.13 (C-3’, C-5’), 131.27
(C-2’, C-6’), 49.60 (d, JCP=122.2 Hz, C-1), 37.16 (acetyl-CH3).
31P NMR
(203 MHz, CD3OD): δ=15.82 ppm. HRMS (ESI): calcd. for C13H21NO4P
[M(acid)+H]+ 258.0526, found: 258.0523.
Ethyl (2-((4-acetylphenyl)amino)-2-oxoethyl)(methyl)phosphinate
(27): Alkyl chloride 21 (113 mg, 0.536 mmol) was dissolved in a
mixture of toluene (2 mL) and THF (2 mL). At 100 °C, diethyl
methylphosphonate (200 μL, 1.33 mmol) was added dropwise over
10 min. The reaction mixture was stirred at 100 °C for 23 h. After
cooling to RT, the solvent was evaporated under reduced pressure,
and the resultant crude product was purified by column chroma-
tography (CH2Cl2/MeOH 98 :2) to give 27 as a white solid (113 mg,
75%). 1H NMR (500 MHz, CDCl3): δ=9.97 (s, 1H, NH), 7.73 (d, J=
8.8 Hz, 2H, 3’-H, 5’-H), 7.51 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 4.19–4.12
(m, 2H, ethyl-1-H), 3.19 (dd, J=18.9, 14.3 Hz, 1H, 1-Ha), 2.99 (dd, J=
14.3, 14.3 Hz, 1H, 1-Hb), 2.50 (s, 3H, acetyl-CH3), 1.72 (d, J=14.5 Hz,
3H, PCH3), 1.37 (t, J=7.0 Hz, 3H, ethyl-2-H) ppm.
13C NMR (126 MHz,
CDCl3): δ=197.02 (acetyl-C=O), 163.42 (d, JCP=3.8 Hz, C-2), 142.54
(C-1’), 132.74 (C-4’), 129.52 (C-3’, C-5’), 118.86 (C-2’, C-6’), 61.57 (d,
JCP=6.5 Hz, ethyl-C-1), 40.35 (d, JCP=81.2 Hz, C-1), 26.48 (acetyl-
CH3), 16.71 (d, JCP=6.2 Hz, ethyl-C-2), 14.78 (d, JCP=97.3 Hz, PCH3)
ppm. 31P NMR (203 MHz, CDCl3): δ=49.31 ppm. HRMS (ESI): calcd.
for C13H18NO4P [M+H]
+ 284.1046, found 284.1043. TLC (CH2Cl2/
MeOH 95 :5): Rf=0.15.
Diethyl (2-((4-acetylphenyl)amino)-2-oxoethyl)phosphonate (28):
Alkyl chloride 21 (146 mg, 0.692 mmol) was suspended in triethyl-
phosphite (2.30 mL, 13.3 mmol) and the reaction mixture was
stirred under reflux for 18 h. After cooling to RT, the solvent was
evaporated under reduced pressure, and the resultant oily crude
product was purified by column chromatography (petroleum ether/
EtOAc 1 :2!1 :5) to give 28 as a white solid (193 mg, 89%). 1H NMR
(500 MHz, CDCl3): δ=9.53 (s, 1H, NH), 7.81 (d, J=8.7 Hz, 2H, 3’-H, 5’-
H), 7.56 (d, J=8.8 Hz, 2H, 2’-H, 6’-H), 4.24–4.18 (m, 4H, ethyl-1-H),
3.08 (d, J=21.1 Hz, 2H, 1-H), 2.53 (s, 3H, acetyl-CH3), 1.38 (t, J=
7.1 Hz, 6H, ethyl-2-H) ppm. 13C NMR (126 MHz, CDCl3): δ=197.03
(acetyl-C=O), 162.61 (d, J=3.9 Hz, C-2), 142.32 (C-1’), 132.94 (C-4’),
129.65 (C-3’, C-5’), 118.98 (C-2’, C-6’), 63.33 (d, JCP=6.8 Hz, ethyl-C-
1), 36.50 (d, JCP=129.3 Hz, C-1), 26.51 (acetyl-CH3), 16.49 (d, JCP=
6.1 Hz, ethyl-C-2) ppm. 31P NMR (203 MHz, CDCl3): δ=22.49 ppm.
MS (ESI): m/z=336.0 [M+Na]+. TLC (CH2Cl2/MeOH 9 :1): Rf=0.55.
FRET-based collagenase inhibition assay: The peptidase domain
(PD) of ColH (Uniprot: Q46085; Leu331-Gly721) and the collagenase
unit of ColQ1 (ColQ1-CU; Uniprot: B9 J3S4; Tyr94-Gly765) were
expressed and purified as previously described.[24] IC50 measure-
ments were performed as previously reported.[13] ColH-PD was
pretreated with the compounds at RT for 1 h. The reaction was
initiated by the addition of 2 μm of the peptide substrate Mca-Ala-
Gly-Pro-Pro-Gly-Pro-Dpa-Gly-Arg-NH2 (FS1-1; Mca= (7-meth-
oxycoumarin-4-yl)acetyl; Dpa=N-3-(2,4-dinitrophenyl)-l-2,3-diami-
nopropionyl). The increase in fluorescence was monitored for 2 min
(λex=328 nm; λem=392 nm) at 25 °C. The final concentrations were
10 nm ColH-PD and 1 nM ColQ1-CU, respectively, 2 μm FS1-1,
250 mm HEPES pH 7.5, 400 mm NaCl, 10 mm CaCl2, 10 μm ZnCl2,
2% DMSO and eight different compound concentrations. The
percentage of enzyme inhibition was calculated in relation to a
blank reference without compound added. All experiments were
performed in triplicates and repeated at least three times. IC50
values were determined using nonlinear regression with a constant
Hill slope of   1. Regression analysis was performed using GraphPad
Prism 5 (Graph Pad Software, San Diego, CA, USA).
MMP inhibition assay: The catalytic domains of MMP-1,   2,   3,
  7,   8, and   14 along with the SensoLyte 520 generic MMP
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assay was performed as previously described using Batimastat as a
positive control[13,25] and according to the guidelines of the
manufacturer.
HDAC inhibition assay: HDAC3 and HDAC8 inhibitor screening kits
were purchased from Sigma–Aldrich. The assay was performed
according to the guidelines of the manufacturer. Fluorescence
signals were measured in a CLARIOstar plate reader (BMG Labtech).
TACE inhibition assay: A TACE (ADAM-17) inhibitor screening assay
kit was purchased from Sigma–Aldrich. The assay was performed
according to the guidelines of the manufacturer. Fluorescence
signals were measured in a CLARIOstar plate reader (BMG Labtech).
Cytotoxicity assay: HepG2, HEK293, or A549 cells (2×105 cells per
well) were seeded in 24-well, flat-bottomed plates. Culturing of
cells, incubations, and OD measurements were performed as
previously described[26] with minor modifications. 24 h after seeding
the cells, the incubation was started by the addition of compounds
at a final DMSO concentration of 1%. The living cell mass was
determined after 48 h. At least two independent measurements
were performed for each compound.
Zebrafish embryo toxicity assay: Toxicity testing was performed
according to the procedure described in the literature[27] with minor
modifications using zebrafish embryos of the AB wild-type line at
1 d post fertilisation (dpf) as previously reported.[16] All of the
described experiments were performed with zebrafish embryos
<120 h post-fertilisation (hpf) and are not classified as animal
experiments according to EU Directive 2010/63/EU. Protocols for
husbandry and care of adult animals were in accordance with the
German Animal Welfare Act (§11 Abs. 1 TierSchG).
Ex vivo pig skin degradation assay: The assay was performed as
previously reported[16] using explants from pig ears in a 24-well
plate. Compound 26 was preincubated with 300 nM of ColQ1,
4 mM CaCl2, 10 μM ZnCl2 in DMEM medium at 37 °C and 5% CO2
for 1 h. After preincubation, one skin explant was added into each
well and incubated at 37 °C and 5% CO2 for 24 h under 300 rpm
shaking. Hydroxyproline release was measured using a hydroxypro-
line assay kit (Sigma–Aldrich) according to the guidelines of the
manufacturer. Absorbance was measured using a PHERAstar plate
reader (BMG Labtech). The absorbance values were converted into
hydroxyproline concentrations (μg/mL) using a calibration curve of
hydroxyproline (Figures S1 and S2 in the Supporting Information).
The absolute concentrations were converted into percentages by
setting the concentration of the 0 μM value to 100% and
calculating all values from each experiment separately.
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